BACKGROUND: The correctional population bears a heavy burden of hepatitis C virus (HCV) infection necessitating expansion of HCV testing and treatment opportunities. Rapid HCV testing provides point-of-care antibody results and may be ideal for correctional facilities, particularly jails, where persons are often incarcerated for short periods of time, yet feasibility has not been established. METHODS: We conducted a pilot study of a rapid HCV testing algorithm among short-term inmates with unknown HCV status. Participants completed a questionnaire, viewed an informational video and underwent rapid HCV testing and confirmatory testing, when indicated. Persons with chronic infection were referred to community care after release. Baseline characteristics, risk behaviors, test results and linkage were examined by descriptive analyses. RESULTS: Two hundred and fifty-two inmates were enrolled and 249 completed all study activities. Twenty-five participants (10%) had reactive rapid tests and 23 (92%) completed confirmatory testing. 15/23 (65%) had detectable HCV RNA, but only 4 linked to care after release. Persons with reactive HCV tests were more likely to be White (P = 0.01) and to have ever injected (P < 0.0001) and/or recently injected (P < 0.0001) drugs. CONCLUSIONS: Rapid HCV testing within jails is feasible, identifies previously unrecognized cases of HCV infection, and implementation should be considered. Low rates of linkage to care after release remain a barrier to care.
BACKGROUND: The correctional population bears a heavy burden of hepatitis C virus (HCV) infection necessitating expansion of HCV testing and treatment opportunities. Rapid HCV testing provides point-of-care antibody results and may be ideal for correctional facilities, particularly jails, where persons are often incarcerated for short periods of time, yet feasibility has not been established. METHODS: We conducted a pilot study of a rapid HCV testing algorithm among short-term inmates with unknown HCV status. Participants completed a questionnaire, viewed an informational video and underwent rapid HCV testing and confirmatory testing, when indicated. Persons with chronic infection were referred to community care after release. Baseline characteristics, risk behaviors, test results and linkage were examined by descriptive analyses. RESULTS: Two hundred and fifty-two inmates were enrolled and 249 completed all study activities. Twenty-five participants (10%) had reactive rapid tests and 23 (92%) completed confirmatory testing. 15/23 (65%) had detectable HCV RNA, but only 4 linked to care after release. Persons with reactive HCV tests were more likely to be White (P = 0.01) and to have ever injected (P < 0.0001) and/or recently injected (P < 0.0001) drugs. CONCLUSIONS: Rapid HCV testing within jails is feasible, identifies previously unrecognized cases of HCV infection, and implementation should be considered. Low rates of linkage to care after release remain a barrier to care.
Authors: Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Leticia de Paula Scalioni; Helena Medina Cruz; Vanessa Salete de Paula; Juliana Custódio Miguel; Vanessa Alves Marques; Cristiane Alves Villela-Nogueira; Flavio Augusto Pádua Milagres; Marcelo Santos Cruz; Francisco Inácio Bastos; Tarcisio Matos Andrade; Ana Rita Coimbra Motta-Castro; Lia Laura Lewis-Ximenez; Elisabeth Lampe; Livia Melo Villar Journal: J Clin Virol Date: 2014-04-13 Impact factor: 3.168
Authors: John Farley; Shawn Vasdev; Benedikt Fischer; Emma Haydon; Jürgen Rehm; Theresa A Farley Journal: Am J Public Health Date: 2005-08-30 Impact factor: 9.308
Authors: Noelle Cocoros; Eduardo Nettle; Daniel Church; Lori Bourassa; Vicki Sherwin; Kevin Cranston; Robert Carr; H Dawn Fukuda; Alfred DeMaria Journal: Public Health Rep Date: 2014 Jan-Feb Impact factor: 2.792
Authors: Scott A Allen; Anne C Spaulding; Albert M Osei; Lynn E Taylor; Asya M Cabral; Josiah D Rich Journal: Ann Intern Med Date: 2003-02-04 Impact factor: 25.391
Authors: Lauren J Stockman; Sheila M Guilfoye; Andrea L Benoit; James M Vergeront; Jeffrey P Davis Journal: MMWR Morb Mortal Wkly Rep Date: 2014-04-11 Impact factor: 17.586
Authors: Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely Journal: Liver Int Date: 2018-09-22 Impact factor: 5.828
Authors: Nadine Kronfli; Camille Dussault; Sofia Bartlett; Dennaye Fuchs; Kelly Kaita; Kate Harland; Brandi Martin; Cindy Whitten-Nagle; Joseph Cox Journal: Can Liver J Date: 2021-08-09
Authors: Brendan P Jacka; Laurie B Bazerman; Collin Dickerson; Marc Moody; Johanna Martin; Emily Patry; Treniece Cady; Hacheming Compere; Matthew Boudreau; Curt G Beckwith Journal: Int J Drug Policy Date: 2022-03-31
Authors: Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore Journal: Int J Drug Policy Date: 2017-07-03
Authors: Alysse G Wurcel; Jessica Reyes; Julia Zubiago; Peter J Koutoujian; Deirdre Burke; Tamsin A Knox; Thomas Concannon; Stephenie C Lemon; John B Wong; Karen M Freund; Curt G Beckwith; Amy M LeClair Journal: PLoS One Date: 2021-05-26 Impact factor: 3.240
Authors: Joshua A Barocas; Benjamin P Linas; Arthur Y Kim; John Fangman; Ryan P Westergaard Journal: Open Forum Infect Dis Date: 2016-04-06 Impact factor: 3.835